Labcorp Appoints New Board Member
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy LH?
Source: Newsfilter
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors on February 9, 2026, leveraging his extensive experience in clinical care and biomedical research to advance the company's strategy in diagnostics and drug development.
- Academic Background: Dr. Sampson serves as vice chancellor and dean at the University of Colorado Anschutz School of Medicine, with nearly 300 peer-reviewed publications focused on advancing new therapies for neurologic diseases, enhancing Labcorp's expertise in personalized medicine and oncology.
- Leadership Experience: Prior to joining CU Anschutz, Dr. Sampson held senior vice president roles at Duke University Health System, where he led integrated practices, showcasing his strong background in large-scale health system leadership that aligns with Labcorp's strategic needs.
- Quality and Compliance Committee: Dr. Sampson's appointment to the Quality and Compliance Committee is expected to utilize his clinical and research experience to further Labcorp's mission of advancing early diagnosis and the development of new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 304.45 USD with a low forecast of 270.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 277.200
Low
270.00
Averages
304.45
High
325.00
Current: 277.200
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors effective February 9, 2026, bringing extensive experience in medicine and biomedical research, which is expected to advance the company's strategy in diagnostics and drug development.
- Professional Background: Dr. Sampson previously served as vice chancellor and dean at the University of Colorado Anschutz School of Medicine and held senior roles at Duke University Health System, with nearly 300 peer-reviewed publications showcasing his expertise in advancing new therapies for neurologic diseases.
- Strategic Alignment: His deep expertise in oncology, neuroscience, and personalized medicine aligns closely with Labcorp's strategic focus, likely enhancing the value delivered to customers.
- Quality Compliance Committee: Following his appointment, Dr. Sampson was also appointed to the Quality and Compliance Committee, further strengthening Labcorp's leadership in quality management and compliance.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors on February 9, 2026, leveraging his extensive experience in clinical care and biomedical research to advance the company's strategy in diagnostics and drug development.
- Academic Background: Dr. Sampson serves as vice chancellor and dean at the University of Colorado Anschutz School of Medicine, with nearly 300 peer-reviewed publications focused on advancing new therapies for neurologic diseases, enhancing Labcorp's expertise in personalized medicine and oncology.
- Leadership Experience: Prior to joining CU Anschutz, Dr. Sampson held senior vice president roles at Duke University Health System, where he led integrated practices, showcasing his strong background in large-scale health system leadership that aligns with Labcorp's strategic needs.
- Quality and Compliance Committee: Dr. Sampson's appointment to the Quality and Compliance Committee is expected to utilize his clinical and research experience to further Labcorp's mission of advancing early diagnosis and the development of new therapies.
See More
Labcorp Holdings Inc. to Release Q4 2025 Financial Results on February 17, 2026
- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
See More
UniFirst Declares $0.365 Dividend, Kaiser Aluminum Announces $0.77 Dividend
- UniFirst Dividend Announcement: UniFirst's Board of Directors declared a quarterly cash dividend of $0.365 per share, payable on March 27, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Kaiser Aluminum Dividend Declaration: Kaiser Aluminum announced a cash dividend of $0.77 per share, payable on February 13, 2026, demonstrating the company's strong performance in maintaining stable cash flow and shareholder returns.
- Agree Realty Dividend Increase: Agree Realty declared a monthly cash dividend of $0.262, with an annualized amount rising to $3.144, a 3.6% increase from Q1 2025, showcasing the company's focus on shareholder value and confidence in profit growth.
- Labcorp Dividend Payment: Labcorp Holdings announced a cash dividend of $0.72 per share, payable on March 12, 2026, indicating its robust financial performance in the innovative laboratory services sector.
See More
Goldman Sachs: AI Automation to Boost Multiple Stocks in 2026
- AI Investment Outlook: Goldman Sachs anticipates a deceleration in AI spending in 2026, while adoption rates increase, potentially causing rotations among major US tech stocks that create two-way risks for the aggregate index.
- EPAM Systems Performance: EPAM Systems has seen strong stock performance since raising its full-year revenue and earnings outlook in early November, with the CEO emphasizing the acceleration of transformation through AI investment and innovation to strengthen strategic positioning in AI-native enterprises.
- Affirm's AI Utilization: Affirm leverages AI to maximize merchant sales, with its AdaptAI providing personalized payment options that drive greater customer engagement, resulting in over a 30% stock price increase over the past year.
- Strong Market Performance: Bank stocks like Bank of America have outperformed the market over the past three months and hit an all-time high last week, indicating strong potential for AI-related stocks.
See More
Labcorp Holdings (LH) Declares $0.72 Quarterly Dividend with 1.13% Yield
- Quarterly Dividend Announcement: Labcorp Holdings has declared a quarterly dividend of $0.72 per share, consistent with previous distributions, indicating the company's stable cash flow and commitment to shareholder returns.
- Yield Information: The forward yield of this dividend stands at 1.13%, reflecting the company's attractiveness in the current market environment, which may draw in more income-focused investors.
- Shareholder Record Dates: The dividend is payable on March 12, with a record date of February 27 and an ex-dividend date also set for February 27, ensuring shareholders receive their payouts promptly.
- Future Outlook: Despite lowering the midpoint of its 2025 revenue guidance, Labcorp still targets an 8% revenue growth, demonstrating the company's ongoing efforts in restructuring and specialty expansion.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors effective February 9, 2026, bringing extensive experience in medicine and biomedical research, which is expected to advance the company's strategy in diagnostics and drug development.
- Professional Background: Dr. Sampson previously served as vice chancellor and dean at the University of Colorado Anschutz School of Medicine and held senior roles at Duke University Health System, with nearly 300 peer-reviewed publications showcasing his expertise in advancing new therapies for neurologic diseases.
- Strategic Alignment: His deep expertise in oncology, neuroscience, and personalized medicine aligns closely with Labcorp's strategic focus, likely enhancing the value delivered to customers.
- Quality Compliance Committee: Following his appointment, Dr. Sampson was also appointed to the Quality and Compliance Committee, further strengthening Labcorp's leadership in quality management and compliance.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors on February 9, 2026, leveraging his extensive experience in clinical care and biomedical research to advance the company's strategy in diagnostics and drug development.
- Academic Background: Dr. Sampson serves as vice chancellor and dean at the University of Colorado Anschutz School of Medicine, with nearly 300 peer-reviewed publications focused on advancing new therapies for neurologic diseases, enhancing Labcorp's expertise in personalized medicine and oncology.
- Leadership Experience: Prior to joining CU Anschutz, Dr. Sampson held senior vice president roles at Duke University Health System, where he led integrated practices, showcasing his strong background in large-scale health system leadership that aligns with Labcorp's strategic needs.
- Quality and Compliance Committee: Dr. Sampson's appointment to the Quality and Compliance Committee is expected to utilize his clinical and research experience to further Labcorp's mission of advancing early diagnosis and the development of new therapies.
See More
Labcorp Holdings Inc. to Release Q4 2025 Financial Results on February 17, 2026
- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
See More
UniFirst Declares $0.365 Dividend, Kaiser Aluminum Announces $0.77 Dividend
- UniFirst Dividend Announcement: UniFirst's Board of Directors declared a quarterly cash dividend of $0.365 per share, payable on March 27, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Kaiser Aluminum Dividend Declaration: Kaiser Aluminum announced a cash dividend of $0.77 per share, payable on February 13, 2026, demonstrating the company's strong performance in maintaining stable cash flow and shareholder returns.
- Agree Realty Dividend Increase: Agree Realty declared a monthly cash dividend of $0.262, with an annualized amount rising to $3.144, a 3.6% increase from Q1 2025, showcasing the company's focus on shareholder value and confidence in profit growth.
- Labcorp Dividend Payment: Labcorp Holdings announced a cash dividend of $0.72 per share, payable on March 12, 2026, indicating its robust financial performance in the innovative laboratory services sector.
See More
Goldman Sachs: AI Automation to Boost Multiple Stocks in 2026
- AI Investment Outlook: Goldman Sachs anticipates a deceleration in AI spending in 2026, while adoption rates increase, potentially causing rotations among major US tech stocks that create two-way risks for the aggregate index.
- EPAM Systems Performance: EPAM Systems has seen strong stock performance since raising its full-year revenue and earnings outlook in early November, with the CEO emphasizing the acceleration of transformation through AI investment and innovation to strengthen strategic positioning in AI-native enterprises.
- Affirm's AI Utilization: Affirm leverages AI to maximize merchant sales, with its AdaptAI providing personalized payment options that drive greater customer engagement, resulting in over a 30% stock price increase over the past year.
- Strong Market Performance: Bank stocks like Bank of America have outperformed the market over the past three months and hit an all-time high last week, indicating strong potential for AI-related stocks.
See More
Labcorp Holdings (LH) Declares $0.72 Quarterly Dividend with 1.13% Yield
- Quarterly Dividend Announcement: Labcorp Holdings has declared a quarterly dividend of $0.72 per share, consistent with previous distributions, indicating the company's stable cash flow and commitment to shareholder returns.
- Yield Information: The forward yield of this dividend stands at 1.13%, reflecting the company's attractiveness in the current market environment, which may draw in more income-focused investors.
- Shareholder Record Dates: The dividend is payable on March 12, with a record date of February 27 and an ex-dividend date also set for February 27, ensuring shareholders receive their payouts promptly.
- Future Outlook: Despite lowering the midpoint of its 2025 revenue guidance, Labcorp still targets an 8% revenue growth, demonstrating the company's ongoing efforts in restructuring and specialty expansion.
See More
